Japan's Eisai establishes new US R&D subsidiary to focus on oncology

31 January 2011

Japanese drug major Eisai (TYO: 4523) says it has established a new R&D subsidiary, called H3 Biomedicine, in Cambridge, Massachusetts, USA, to strengthen its research in oncology, and the company's research activities are underway.

H3B aims to discover breakthrough cancer drugs based on two research objectives: the identification of drug targets in order to facilitate individualized medical care based on the genetic characteristics of each cancer patient, and the active utilization of technologies based on advances in contemporary drug discovery chemistry in order to create new classes of safe and effective compounds that interact with these drug targets. H3B will use the latest findings to discover new cancer drugs that lead to individualized care.

$200 million funding to be provided

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK